Patient-Clinician Perspectives

Xenon Presents Phase 3 Azetukalner Results and 48‑Month Data at American Academy of Neurology Meeting

The conference disclosures offer an early view of late‑stage results alongside long‑term follow‑up for a new KV7 therapy.